Prospective randomized investigation implementing immunonutritional therapy using a nutritional supplement with a high blend ratio of ω-3 fatty acids during the perioperative period for head and neck carcinomas 
Introduction
In patients with head and neck carcinoma, the nutritional condition is likely to deteriorate due to swallowing disorder and as a consequence of highly invasive treatment. Recent studies have focused on the relationship between the nutritional status of cancer patients and cancer cachexia. Cancer cachexia is defined as a syndrome in which patients exhibit mixed metabolic disorders and nutritional disorders causing weight loss due to the nutritionally and immunologically exhausted condition of the host (1) . Inflammatory cytokines (e.g. interleukin 6 ) are known to induce cachexia. These accelerate the proliferation of cancer by vascularization and affect all types of metabolism and immunological reactivity (2) . Cachexia is oncologically assumed to be an independently associated with a poor prognosis during the clinical stage.
The European guidelines for palliative care (3) propose three stages of cachexia: 'precachexia,' 'cachexia' with reversible malnutrition and 'refractory cachexia' with irreversible malnutrition, which is the stage at which the significance of nutritional management is recognized. It is currently assumed that the inhibition of inflammatory cytokines can inhibit the advancement of cachexia. Thus, it is presumed that it is desirable to perform immunonutrition for cancer cachexia from an early stage in order to maintain the nutritional status (4) .
Ω-3 fatty acids are known to inhibit the production of inflammatory cytokines and inflammatory reactions in a wide variety of cancer patients (5) . Fearon et al. reported that weight gain, as well as an improved QOL, were exhibited after the administration of nutritional supplements, including eicosapentaenoic acid (EPA) to patients with unresectable and advanced pancreatic carcinoma, in comparison to those who consumed nutritional food under the same conditions without EPA (6) . Another study reported that the administration of nutritional supplements inhibited weight loss after surgery in patients with carcinoma of the esophagus (7). Recently, Weed et al. reported that the maintenance of postoperative weight and skeletal muscle was found after interventions in patients with head and neck carcinomas and weight loss before surgery (8) . However, the effects with regard to the improvement of the nutritional status and the inhibition of inflammation in patients with head and neck carcinomas remain unknown. In this study, we carried out nutrition intervention using nutritional supplements, including EPA.
Patients & methods

Subject
Subjects who met all of the following eligibility criteria and none of the exclusion criteria at the time of giving their informed consent were eligible for inclusion in the present study.
Eligibility criteria: (1) histopathologically diagnosed head and neck squamous cell carcinoma, (2) indication for free flap reconstruction, (3) the subject intended to participate in this test and provided their written consent, (4) the age at the time of registration was 20-80 years, (5) an ECOG performance status of 0-2, (6) ≥5% weight loss within the past 6 months, (7) life expectancy ≥6 months and (8) the patient's major organ function was maintained.
Patients who met any of the following exclusion criteria were excluded from the study: (1) intestinal occlusion and serious enterostenosis (enteral feeding intolerance), (2) combined resection of other organs, (3) obvious focal infection before surgery, (4) serious heart, liver or kidney disease, (5) uncontrolled diabetes, (6) refractory hyperlipemia, (7) a past history of chronic inflammatory disease, (8) continuous or general administration (oral or intravenous) of steroids, (9) subjects taking EPA, (10) a past history of anaphylaxis against components of Prosure ® (e.g. milk and soybean), (11) patients who are pregnant, lactating or possibly pregnant and (12) patients who were deemed ineligible for other reasons by the principal investigator of the test. This study was approved by the ethics board of the Aichi Cancer Center Hospital (IRB number 4-37) and was carried out in accordance with the Declaration of Helsinki and the ethical guidelines for clinical studies (MHLW Notification No. 255). During patient recruitment, the patients were provided with a detailed explanation of this study. Written informed consent was obtained from all of the patients who participated in the present study.
Research design
A schematic illustration of the study design is shown in Fig. 1 . The subjects were patients undergoing head and neck cancer surgery who required resection and free flap reconstruction and who exhibited ≥5% weight loss. After confirming their eligibility, they were randomized into an experimental arm (nutritional supplementation group), in which an EPA-enriched oral nutritional supplement (Prosure ® ) was administered, and a control arm (non-intervention group). The administration period for Prosure ® was from 14 days before surgery until 14 days after surgery. The primary endpoints included the postoperative nutritional status (weight, lean body mass, albumin, prealbumin), while the secondary endpoints included inflammatory marker levels (CRP, IL6, white blood cell count, body temperature), compliance with the Prosure ® dosage, and the occurrence of postoperative complications. The weight and lean body mass were measured before administration, on the day prior to surgery, and on the seventh and 14th days after surgery. Albumin, CRP, WBC and body temperature were measured before administration, on the day prior to surgery, and on Days 1, 3, 7 and 14 after surgery. Prealbumin was also measured after surgery. IL6 and the fatty acid fraction were measured before administration and on the 14th day after surgery.
The methods of Prosure ® administration Prosure ® was administered at a dose of two packs per day (480 ml) during the period from 14 days before surgery until 14 days after surgery in addition to a normal diet (or in lieu of part of a normal diet).
In the event that the dietary intake was insufficient, we gave priority to the administration of Prosure ® . In the event that the total dose of Prosure ® could not be administered, we determined the amount remaining using a measuring cup and recorded it. We did not regulate the time of intake. The dietary intake was not limited. The nutritional content of the Prosure ® supplement in this study is shown in Table 1 .
EPA is known to inhibit the production of inflammatory cytokines and inflammatory reactions in a wide variety of cancer patients (9) , and it is possible to take 2 g of EPA in two packs per day with zinc, vitamin C and E.
Statistical analysis
In the previous examination of patients with advanced cancer of the pancreas, the change in weight was +1 (−0.1 to +2.8) kg and −2.8 (−3.7 to −1.7) kg, respectively, during the 4-week testing period in 18 cases each of the experimental arm and control arm. Given an equivalent effect and distribution, and a standard deviation of 3 kg, nine subjects in each arm would be required to detect a statistically significant difference by Student's t-test [α = 0.1 (bilateral), 1 − β = 0.8]. The setting of 15 subjects per arm allowed for the possible drop-out of six patients in each arm. For the intent-to-treat analysis, the object of the analysis included the registered subjects in each arm.
Regarding the primary endpoint, we tested the difference in the measured values of the two arms using Student's t-test (when homogeneity of variance existed between the arms) or Welch's t-test [α = 0.1 (bilateral), 1 − β = 0.8] when it did not. Regarding the evaluation of inflammatory markers (CRP, IL6, white blood cell count, body temperature), which were secondary endpoints, we tested the difference the changes in the measured values between the arms during the intraoperative period (2 weeks before surgery to 2 weeks after surgery), using Student's t-test (when homogeneity of variance existed between the arms) or Welch's t-test (when it did not). Regarding compliance with the Prosure ® dosage, we tested the difference between the arms in terms of the change in values during the intraoperative period (2 weeks before surgery to 2 weeks after surgery) using the Wilcoxon signed-rank sum test. We tested the difference between the arms in terms of the occurrence of complications using Fisher's exact test.
Results
Patient characteristics
At the end of registration, there were 13 in the experimental arm and 14 cases in the control arm. There were no significant differences in the background factors of the patients in the two arms ( Table 2 ). The average age was 61.5 (range, 45-77) years in the experimental arm, and 66.1 (range, 47-76) years in the control arm. The average weight loss was 9.6 (range, 5.0-19.6) kg in the experimental arm, and 8.8 (range, 5.0-15.7) kg in the control arm. The presence/absence of preoperative treatment (e.g. induction chemotherapy) was not included in the eligibility criteria. Seven of the 13 patients in the experimental arm and 8 of the 14 patients in the control arm received preoperative chemotherapy.
Primary endpoint: postoperative nutritional status (weight, lean body mass, albumin, prealbumin)
The results that reflected the postoperative nutritional status (the primary endpoint) are shown. Figures 2A, B, 3A and B illustrate body weight, lean body mass, albumin and prealbumin, respectively. All of the plotted data are shown as the mean ± standard deviation. The changes in body weight, lean body mass and albumin from baseline until the 14th day after surgery did not differ to a statistically significant extent (body weight, P = 0. Compliance with respect to the number of days of administration was 98% (13.7 days) before surgery and 80% (11.2 days) after surgery. This is due to the fact that there was a blank period of~2 days (average) before the initiation of tube feeding. Compliance with respect to the dosage was 93% (6277/6720 ml) (average) before surgery and 78% (5229/6720 ml) after surgery. The average dose before surgery 458 ml/day (95%), while that after surgery was 460 ml/day (96%). The result did not differ to a statistically significant extent (Wilcoxon signed-rank test, P > 0.10) and the compliance was considered to be good at both measurement points.
The concentration of EPA, as expected, showed a significant increase in the experimental arm (Welch's t-test, P < 0.0001) (Fig. 6) 
Occurrence of postoperative complications
As Table 3 shows, Grade ≥2 complications (Clavien-Dindo classification) (10) were found in four cases (31%) in the experimental arm and six cases (43%) in the control arm, and did not differ to a statistically significant extent (Fisher's exact test) . Similarly, Grade ≥3 complications were found in four cases (31%) in the experimental arm and five cases (36%) in the control arm, and did not differ to a statistically significant extent (Fisher's exact test).
Comparison of calorie intake
In order to minimize the difference in calorie to be administered, an appropriate alternative method was used when the oral intake was insufficient. For example, nasogastric tube feeding or peripheral parenteral nutrition were used in combination.
Perioperative calorie intake for these patients is shown in Table 4 . There was no significant difference in caloric intake from normal diet or alternative nutrition in both arms. In the experimental arm, total calorie tended to increase because Prosure ® was added to normal diet, but no significant difference was observed.
Discussion
We used Prosure ® as a nutritional supplement with a high blend ratio of ω-3 fatty acids (EPA) and examined its effects in improving the nutritional status and inhibition of inflammation. Thus, patients with precachexia or cachexia (≥5% body weight loss within 6 months) were included in the present study, as the represented targets of aggressive nutrition intervention according to the European guidelines for palliative care. The cases were limited to patients with highly invasive head and neck cancer requiring resection and free flap reconstruction. There were no significant differences in the results. One major factor in this was that the average weight change in the perioperative period was lower than anticipated. Gourin et al. reported that surgical or medical complications after surgery, the duration of hospital stay, and the cost of treatment were significantly associated with body weight loss in patients undergoing surgery for head and neck carcinoma. Other factors that have been reported to be associated with body weight loss include major surgical procedures, comorbidity, dysphagia, postoperative wound infection and complications (11) . Regarding the involvement of complications and dysphagia, patients with serious complications were excluded from the study; furthermore, because we observed the changes during the relatively early stages after surgery, the impact of dysphagia was subtle, as nutrition was provided throughout most of the postoperative period depending on tube feeding. The administration period was set based on a clinical trial in which Prosure ® was administered during the perioperative period to patients undergoing head and neck cancer surgery (8) . The authors of the study reported that the lean body mass was increased by 3 weeks of ingestion, which was started at least 2 weeks before the operation. Thus, it was administered from 2 weeks before the operation. After major head and neck surgery, a patient requires~2 weeks of tube feeding. They are discharged when oral intake becomes possible; thus, 2 weeks after the operation is an appropriate period of perioperative nutrition management. In this respect, as the duration of chemoradiotherapy (which is associated with eating difficulty) for head and neck carcinoma is long, nutrition management can be expected to have an impact on body weight loss. Pramyothin et al. reported that weight loss during chemoradiotherapy for head and neck carcinoma ranged from 3.1 to 4.8 kg (12), which is greater than the body weight loss that was observed in the present study. We observed a significant increase in EPA levels with good compliance to the Prosure ® dosage. However, there were no significant differences in the inflammatory marker levels. Resolvin E and D, which originate from ω-3 fatty acids, are known to suppress toll-like receptor 4 signaling, reduce IL-6 levels (an inflammatory cytokine) (13) , and prevent uncontrolled neutrophil swarming (14) . These are anticipated to be beneficial to cancer patients in terms of nutrition managements that focus on immunonutritional therapy. In the present study, the change in the IL-6 level and the white blood cell count appeared to be slightly lower in the experimental arm; however, it might be difficult to find a statistically significant difference without increasing the number of subjects.
Conclusion
The results of this study indicate that for patients who are considered to already have cachexia (based on body weight loss), perioperative nutritional supplementation for 28 days does not have a significant effect on body weight change or inflammatory marker levels. We described the surgery-related changes in inflammatory marker levels in patients undergoing head and neck cancer surgery. Going forward, we will seek more effective subjects and methods of nutritional supplementation. Further investigation is therefore required. 
